Sinopharm, Sinovac Biotech and Gan & Lee Pharmaceuticals all took part in the liquid chromatography technology provider’s series D round.

China-based liquid chromatography product developer Suzhou Sepax Technologies has received $78.4m in a series D round featuring vaccine developer Sinovac Biotech and pharmaceutical firms Sinopharm and Gan & Lee Pharmaceuticals, DealStreetAsia has reported.

Hedge fund manager Hillhouse Capital led the round through its venture capital arm, GL Ventures, and it included Citic Private Equity, Sherpa Healthcare Partners and unnamed others.

Suzhou Sepax is a subsidiary of US-headquartered Sepax Technologies, which was founded in 2002 and which provides products for liquid…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn